Skip to main
TYRA
TYRA logo

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences Inc. holds a strong positive outlook due to its innovative precision medicine platform, SNAP, which enables swift and accurate drug design, positioning the company favorably within the biotechnology sector. The potential of TYRA-300, particularly in its ability to achieve meaningful improvements in patient outcomes such as height velocity and overall tolerability, presents a significant advancement over existing therapies. Moreover, the first oral FGFR3 therapy is anticipated to revolutionize treatment paradigms, demonstrating promising compliance and market uptake driven by established infrastructure, suggesting a robust commercial opportunity in the near future.

Bears say

Tyra Biosciences Inc reported a significant net loss of $25.6 million, or ($0.43) per share, which aligns closely with prior estimates but raises concerns about the company's financial sustainability. The company faces substantial risks regarding potential delays in the clinical development of its drug candidates TYRA-300 and TYRA-200, negative clinical outcomes, regulatory approvals, and competition from existing therapies that may hinder commercial success. Furthermore, the reported adverse effects associated with existing FGFR inhibitors underscore the challenges that Tyra's candidates must overcome to differentiate themselves in a competitive market.

Tyra Biosciences (TYRA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.